老字号推“新”举措，经营质效全面提升

Core Viewpoint - The company Beijing Tongrentang (600085) demonstrates strong resilience and vitality amidst complex economic challenges, with total assets increasing from 21.838 billion to 31.198 billion from 2020 to 2024, and reaching 31.819 billion by Q3 2025, driven by new initiatives and strategies [1]. Group 1: Business Strategies - The company focuses on three major development strategies: high-quality development, large product variety, and premium product strategy, which collectively guide its path towards excellence [2][3]. - The high-quality development strategy emphasizes six aspects: high-quality party building, research, production, marketing, management, and talent, aiming for sustainable growth [2]. - The large product variety strategy aims to enhance key products' competitiveness, thereby boosting overall market scale and efficiency [2]. - The premium product strategy focuses on maintaining high quality from production to delivery, ensuring consumer trust through "zero defects" [3]. Group 2: Modern Management System - The company has established a modern enterprise management system, including three control centers for production, quality, and finance, enhancing governance and operational efficiency [4][6]. - The production control center optimizes production layouts and resource sharing, while the quality control center ensures adherence to high standards and "zero defect" management [4]. - The financial control center focuses on data integration and cost control, promoting financial data visualization [4][5]. Group 3: Industry Layout Optimization - The company is actively optimizing its industrial layout in response to favorable policies for traditional Chinese medicine, including acquiring a 51% stake in Shandong Tianyi Pharmaceutical to enhance regional market coverage [7][8]. - A new production base in Hubei is being established to expand capacity in the medicinal liquor sector, aiming to lower costs and increase production efficiency [7]. - The company is also reforming raw material procurement to ensure timely supply and quality control, particularly for rare and endangered medicinal materials [8].